Knopp Biosciences Receives Key Patent Directed to Ion Channel Activators for Brain Disorders

Knopp Biosciences LLC announced it has received the patent entitled “Benzoimidazol-1,2-yl amides as Kv7 channel activators” The patent strengthens the company’s efforts directed to a series of orally available small molecules for treatment of epilepsy, neuropathic pain, and other neurological disorders. Knopp expects initially to advance its lead Kv7 activators in a rare disorder associated with inherited mutation in the KCNQ2 gene to treat severe epilepsy in newborns and infants, for whom conventional anti-seizure medications are insufficient or ineffective. Read more…


Comments are closed.